NCT03928379View on ClinicalTrials.gov

A Study of LY3305677 in Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 27, 2019

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3305677

Administered SC

DRUG

Placebo

Administered SC

Trial Locations (1)

41460

Profil Institut für Stoffwechselforschung, Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03928379 - A Study of LY3305677 in Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter